62 studies found for:    burzynski
Show Display Options
Rank Status Study
21 Unknown  Antineoplaston Therapy in Treating Patients With Brain Stem Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
22 Withdrawn Antineoplaston Therapy in Treating Women With Advanced Breast Cancer
Conditions: Stage IV Breast Cancer;   Recurrent Breast Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological  therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
23 Unknown  Antineoplaston Therapy in Treating Patients With Meningioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
24 Unknown  Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
25 Unknown  Antineoplaston Therapy in Treating Patients With Primary Liver Cancer
Condition: Liver Cancer
Intervention: Drug: antineoplaston A10
26 Unknown  Antineoplaston Therapy in Treating Patients With Stomach Cancer
Condition: Gastric Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
27 Unknown  Antineoplaston Therapy in Treating Women With Stage IV Breast Cancer
Condition: Breast Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
28 Unknown  Antineoplaston Therapy in Treating Patients With Ependymoma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
29 Withdrawn Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer
Conditions: Stage IV Breast Cancer;   Recurrent Breast Cancer
Interventions: Drug: antineoplaston A10;   Drug: methotrexate;   Procedure: alternative product therapy;   Procedure: biological  therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: chemotherapy;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
30 Unknown  Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
31 Unknown  Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer
Condition: Lung Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
32 Unknown  Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
33 Unknown  Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer
Condition: Colorectal Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
34 Unknown  Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin
Condition: Carcinoma of Unknown Primary
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
35 Unknown  Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer
Condition: Lung Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
36 Unknown  Antineoplaston Therapy in Treating Patients With Soft Tissue Sarcoma
Condition: Sarcoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
37 Unknown  Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
38 Withdrawn Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma
Conditions: Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological  therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
39 Unknown  Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
40 Unknown  Antineoplaston Therapy in Treating Patients With Recurrent or Refractory High-Grade Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years